ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Bluejay Diagnostics Inc

Bluejay Diagnostics Inc (BJDX)

0.5631
-0.0078
( -1.37% )
Updated: 05:44:14

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.5631
Bid
0.5588
Offer
0.565
Volume
296,097
0.535 Day's Range 0.575
0.342139 52 Week Range 13.9799
Market Cap
Previous Close
0.5709
Open
0.575
Last Trade
200
@
0.5631
Last Trade Time
05:44:14
Financial Volume
US$ 163,882
VWAP
0.553475
Average Volume (3m)
659,063
Shares Outstanding
563,969
Dividend Yield
-
PE Ratio
-0.03
Earnings Per Share (EPS)
-17.65
Revenue
-
Net Profit
-9.95M

About Bluejay Diagnostics Inc

Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the... Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
Bluejay Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker BJDX. The last closing price for Bluejay Diagnostics was US$0.57. Over the last year, Bluejay Diagnostics shares have traded in a share price range of US$ 0.342139 to US$ 13.9799.

Bluejay Diagnostics currently has 563,969 shares in issue. The market capitalisation of Bluejay Diagnostics is US$321,969.90 . Bluejay Diagnostics has a price to earnings ratio (PE ratio) of -0.03.

BJDX Latest News

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...

Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study...

Bluejay Diagnostics Announces Reverse Stock Split

ACTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0569-9.177419354840.620.670.5356828540.59491903CS
4-2.1169-78.98880597012.683.77010.539543170.88710542CS
12-0.0407-6.740642596890.60383.77010.3421396590630.69225155CS
26-0.3869-40.72631578950.953.77010.3421393198240.69916891CS
52-4.6829-89.26610751055.24613.97990.3421394818794.32898225CS
156-108.8369-99.4852833638109.41250.34213965768025.20107444CS
260-108.8369-99.4852833638109.41250.34213965768025.20107444CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMBCambium Bio Ltd
AUD 0.40
(9,900.00%)
2k
LRLLabyrinth Resources Ltd
AUD 0.015
(200.00%)
42.23M
VPRVolt Group Ltd
AUD 0.002
(100.00%)
343.18k
TD1Tali Digital Limited
AUD 0.0015
(50.00%)
10k
PRXProdigy Gold NL
AUD 0.003
(50.00%)
1.47M
RHYORhythm Biosciences Limited
AUD 0.005
(-75.00%)
916
JTLJayex Technology Limited
AUD 0.001
(-50.00%)
1.34M
EDEEden Innovations Ltd
AUD 0.001
(-50.00%)
79k
DTIDTI Group Limited
AUD 0.009
(-35.71%)
4.16k
SI6Si6 Metals Limited
AUD 0.002
(-33.33%)
2.8M
ATHAlterity Therapeutics Ltd
AUD 0.007
(40.00%)
154.34M
AMDArrow Minerals Limited
AUD 0.003
(20.00%)
123.6M
FBRFBR Limited
AUD 0.05
(4.17%)
64.55M
MRQOMRG Metals Limited
AUD 0.001
(0.00%)
43.5M
LRLLabyrinth Resources Ltd
AUD 0.015
(200.00%)
42.23M

BJDX Discussion

View Posts
Monksdream Monksdream 1 week ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 2 weeks ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 3 weeks ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 3 weeks ago
BJDX new 52 week low
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
I am surprised they were able to make it move with this PR.
👍️0
Awl416 Awl416 3 weeks ago
That was quick

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
👍️0
Monksdream Monksdream 3 weeks ago
Whoops, I did it, again
👍️0
glenn1919 glenn1919 3 weeks ago
BJDX.................................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783
👍️0
richrichrich richrichrich 4 weeks ago
Yes......Sad but true.....
I wish the SEC would change the rules, about doing a RS......Make it really hard to get permission......
Sorry.....Your only other choices are to create more shares, de=list, or die.....
JMO
👍️0
tw0122 tw0122 4 weeks ago
Reverse split $2.71 keep an eye next few weeks for bottom
👍️0
glenn1919 glenn1919 1 month ago
BJDX...............................https://stockcharts.com/h-sc/ui?s=BJDX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 1 month ago
BJDX another round .54
👍️0
tw0122 tw0122 1 month ago
BJDX on its way back to the Moon
👍️0
Monksdream Monksdream 3 months ago
BJDX new 52 lo
👍️0
Monksdream Monksdream 3 months ago
BJDX new 52 lo
👍️0
Monksdream Monksdream 4 months ago
BJDX 10Q due 4/21
👍️0
Monksdream Monksdream 6 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 6 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
BJDX new 52 week low
👍️0
jobynimble jobynimble 8 months ago
Press release on eps: https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/ea187862ex99-1_bluejay.htm

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

Acton, Massachusetts, November 9, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2023.

“Based on FDA’s feedback from the August 11, 2023, meeting, the Company focused on implementing the modified clinical strategy that puts us on the most efficient pathway and believes that it would submit for regulatory approval for Symphony IL-6 during the first half of 2024 as planned. Furthermore, we have re-negotiated our licensing agreement with Toray Industries, Inc. to include a reduced royalty payment from 15% to 7.5% of net sales of certain cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. The new license agreement contemplates that applicable royalty payment obligations from the Company to Toray for other products will be determined separately by the parties in the future. Overall, the re-negotiated licensing agreement provides Bluejay with more freedom to operate, and better secures long-term licensing of Toray’s patents and know-how around the Symphony technology In addition, we have re-negotiated our supply agreement with Toray Industries, Inc. to ensure critical Symphony Cartridge component supply that will sustain us through clinical studies,” said Neil Dey, CEO of Bluejay Diagnostics.

Symphony IL-6 has the potential to be an influential tool for the prediction of clinical deterioration in sepsis patients. Symphony IL-6 testing, in conjunction with clinical and other diagnostic findings, may enable healthcare providers to better prioritize appropriate care to help improve outcomes for those at high risk, and potentially avoid unnecessary investigations and treatments in those at low risk. IL-6 appears as a ‘first responder’ inflammatory biomarker in blood during inflammation, which is common in diseases and infections. A current unmet challenge for healthcare professionals is the amount of time it takes to identify sepsis in patients and to determine disease severity. Existing technologies typically take several hours to deliver IL-6 results, which can delay critical treatment decisions that could improve patient outcomes.

“We are confident that our planned clinical and analytical studies may support a 510(k) FDA regulatory submission with an initial indication for risk stratification of hospitalized sepsis patients. In order for us to realize this, we have continued to limit our cash burn while executing our clinical and regulatory strategy for the Symphony IL-6 test,” said Neil Dey, CEO of Bluejay Diagnostics.

Financial Results for the Three Months Ended September 30, 2023

Cash and cash equivalents. Cash and cash equivalents on September 30, 2023 were $5.08 million, as compared to $10.1 million on December 31, 2022. The Company has maintained a slow cash burn during its FDA submission process. The Company estimates cash resources will be sufficient to fund its operations into the first quarter of 2024. The Company will need additional capital to fund its planned operations for the next 12 months. The Company expects that it will seek to raise such additional capital through public or private equity offerings, grant financing and support from governmental agencies, convertible debt, collaborations, strategic alliances and distribution arrangements.

Research and development expense. Research and development expenses for the three and nine months ended September 30, 2023 were $1.39 million and $4.42 million, respectively, as compared to $1.37 million and $2.83 million, respectively, for the comparable periods in 2022. The increase in research and development expenses is due to the expansion of our clinical program and to support scale-up manufacturing of the Symphony technology platform and IL-6 Test.

General and administrative expense. General and administrative expenses for the three and nine months ended September 2023 were $0.96 million and $3.21 million, respectively, as compared to $1.28 million and $3.8 million, respectively, for the comparable periods in 2022. The decrease in general and administrative expenses reflects the Company’s focus on clinical program and manufacturing scale-up.

Sales and marketing expense. Sales and marketing expenses for the three and nine months ended September 30, 2023 were $(19,619) and $282,756, respectively, as compared to $146,102 and $281,144, respectively, for the comparable periods in 2022. While these expenses have been limited to date, we expect to increase these efforts when appropriate to support our commercial growth.

Net loss/Net loss per share. The net loss for the three and nine months ended September 30, 2023 was $2.29 million and $7.65 million, or $2.08 and $7.30 per share, respectively, compared to $2.9 million and $6.9 million, or $2.94 and $6.86 per share, respectively, for the comparable periods in 2022.

About the SymphonyTM System:

Bluejay’s Symphony System (the “Symphony System”) is designed to address the need for simple, reliable, rapid, near-patient testing by providing quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring. The user-friendly Symphony System will not require any sample preparation or dedicated staff and was shown in published clinical studies to deliver results in approximately 20 minutes.

The Symphony IL-6 Test is a development stage product candidate for investigational use only. It is limited by United States law to investigational use.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis triage, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements in this press release include, without limitation, the ability of the Company to submit a marketing application with the FDA in the first-half of 2024 whether the Company’s cash position will be sufficient to fund operations beyond the date of its anticipated regulatory approval and initial commercialization of the Symphony IL-6 Test, and whether such anticipated regulatory approval will actually occur. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest”, “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events.

Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
Tel: 978-631-0310
Email: neil.dey@bluejaydx.com
👍️0
jobynimble jobynimble 8 months ago
8-K: https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390023085197/ea187862-8k_bluejay.htm

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2023, Bluejay Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 and a corporate update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description
99.1 Press release dated November 9, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
👍️0
jobynimble jobynimble 8 months ago
10-Q out…

https://www.sec.gov/Archives/edgar/data/1704287/000121390023085215/f10q0923_bluejay.htm
👍️0
make it happen make it happen 9 months ago
This will lose a decimal point and will be doing another one in my honest opinion
👍️0
Invest-in-America Invest-in-America 10 months ago
BJDX: I myself made it SOAR --- vis-a-vis my PSYCHO (excuse me, PSYCHIC) powers!!!!



Sincerely yours,
That-Nut-Job
San Diego, CA
👍️0
subslover subslover 10 months ago
Been searching everywhere and can't find news or any reason for this explosion.
👍️0
TheFinalCD TheFinalCD 10 months ago
https://finance.yahoo.com/news/bluejay-diagnostics-announces-1-59-120000291.html

https://finviz.com/quote.ashx?t=BJDX&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/BJDX
👍️0
Monksdream Monksdream 10 months ago
Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
make it happen make it happen 10 months ago
Where can I get locates?!
👍️0
Awl416 Awl416 10 months ago
News?
👍️0
Monksdream Monksdream 10 months ago
BJDX new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BJDX new 52 week low
👍️0
jobynimble jobynimble 11 months ago
8-K filing: https://www.sec.gov/Archives/edgar/data/1704287/000121390023071272/ea184305-8k_bluejay.htm

Item?1.01. Entry into a Material Definitive Agreement.

Securities Purchase Agreement

On August 24, 2023, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 216,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $7.365 per share (the “Offering”).

In a concurrent private placement, the Company also issued to such institutional and accredited investors unregistered warrants to purchase up to 216,000 shares of Common Stock (the “Warrants”). Pursuant to the terms of the Purchase Agreement, for each share of Common Stock issued in this offering, an accompanying Warrant was issued to the purchaser thereof. Each Warrant is exercisable for one share of Common Stock (the “Warrant Shares”) at an exercise price of $7.24 per share, will be immediately exercisable upon issuance and will expire five years from the date of issuance. The Warrants were offered and sold at a purchase price of $0.125 per underlying warrant share, which purchase price is included in the offering price per share of Common Stock issued in the Offering (the “Private Placement”). The gross proceeds to the Company from the Offering and the Private Placement are approximately $1.59 million, before deducting placement agent fees and offering expenses. Neither the Warrants nor the Warrant Shares, have been registered under the Securities Act of 1933, as amended.

Pursuant to an engagement letter, dated as of August 7, 2023 (the “Engagement Letter”), between the Company and H.C. Wainwright & Co., LLC, or the placement agent, the Company agreed to pay the placement agent a total cash fee equal to 7.0% of the gross proceeds received in the Offering and the Private Placement. The Company also agreed to pay the placement agent in connection with the Offering and the Private Placement a management fee equal to 1.0% of the gross proceeds raised in the Offering and Private Placement, $45,000 for non-accountable expenses, and $15,950 for clearing fees. In addition, the Company agreed to issue to the placement agent, or its designees, warrants to purchase up to 15,120 shares of Common Stock (the “Placement Agent Warrants”), which represents 7.0% of the aggregate number of shares of Common Stock sold in the Offering. The Placement Agent Warrants have substantially the same terms as the Warrants, except that the Placement Agent Warrants have an exercise price equal to $ 9.2063, or 125% of the offering price per share of Common Stock sold in the Offering, and a term of five years from the commencement of the sales pursuant to the Offering.

The Offering and Private Placement closed on August 28, 2023.

Pursuant to the terms of the Purchase Agreement, the Company is prohibited from entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of Common Stock or securities convertible or exercisable into Common Stock for a period commencing on August 24, 2023 and expiring 15 days from the closing date of the Offering. Furthermore, the Company is also prohibited from entering into any agreement to issue Common Stock or Common Stock Equivalent (as defined in the Purchase Agreement) involving a Variable Rate Transaction (as defined in the Purchase Agreement), subject to certain exceptions, for a period commencing on August 24, 2023 and expiring one year from the closing date of the Offering.

If a Fundamental Transaction (as defined in the Warrants and Placement Agent Warrants) occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that we may exercise and will assume all of the Company’s obligations under the Warrants and the Placement Agent Warrants with the same effect as if such successor entity had been named in the Warrants and the Placement Agent Warrants itself. If holders of shares of Common Stock are given a choice as to the securities, cash or property to be received in such a Fundamental Transaction, then the holder shall be given the same choice as to the consideration it would receive upon any exercise of the Warrants and the Placement Agent Warrants following such a Fundamental Transaction. Additionally, as more fully described in the Warrants and the Placement Agent Warrants, in the event of certain Fundamental Transactions, the holders of Private Warrants will be entitled to receive consideration in an amount equal to the Black Scholes value of the Private Warrants on the date of consummation of such Fundamental Transaction.

The 216,000 shares of Common Stock sold in the Offering (but not the Warrants or the Warrant Shares) were offered and sold pursuant to a prospectus supplement, dated August 24, 2023, and accompanying prospectus, in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-272432), which registration statement was filed on June 5, 2023 and declared effective on June 20, 2023. A copy of the opinion of Hogan Lovells US LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1.

The Warrants, the Warrant Shares, the Placement Agent Warrants and the shares of Common Stock issuable thereunder were sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors.

Item 3.02. Unregistered Sales of Equity Securities.

The disclosures in Item 1.01 of this Form 8-K regarding the Warrants, and Warrant Shares, the Placement Agent Warrants and the shares of Common Stock issuable thereunder are incorporated by reference into this Item 3.02.
👍️0
Invest-in-America Invest-in-America 11 months ago
HUGE movement; rumor has it big contract for their primary GADGET.
👍️0
Awl416 Awl416 11 months ago
Movement
👍️0
retireat40 retireat40 12 months ago
Got pumped for 30 mins again today. Doesn’t change the fact that this is a low float pump.
👍️0
Stockexpertpro Stockexpertpro 12 months ago
INVO 1 for 20 Reverse stock split micro float like VIEW Yesterday
👍️0
Triple nickle Triple nickle 12 months ago
Lmao
👍️0
retireat40 retireat40 12 months ago
Low float pump job. Appears dead for now.
👍️0
retireat40 retireat40 12 months ago
Probably not
👍️0
Pt3 Pt3 12 months ago
Yes 50 before 5
👍️0
slowd slowd 12 months ago
It can really go to 5 haha
👍️0
Pt3 Pt3 12 months ago
Can this really 50
👍️0
TheFinalCD TheFinalCD 12 months ago
13.98 to 11.32 real quick HALT down coming??
👍️0
Awl416 Awl416 12 months ago
What the F
👍️0
AJ Freely AJ Freely 12 months ago
$BJDX - Up 5.7% Pre-Market/ Current Price $0.27
Announces Reverse Stock Split of 1:20
Reducing the OS from 100m down to 7.5m
Effective July 24, '23
👍️0
Triple nickle Triple nickle 1 year ago
Nice pop
👍️0
makinezmoney makinezmoney 1 year ago
$BJDX: Manoah backkkkkkkkkkkkk in the lineup today...............


Now 0.40.............. must be why





GO $BJDX
👍️0
Jess070283 Jess070283 1 year ago
Weeeeee! $$$$
👍️0
makinezmoney makinezmoney 1 year ago
$BJDX: Heres the move now......... from $0.25 to $0.32


And shesssssssssss off the bbottom.......... gooooooooooooooo



GO $BJDX
👍️0
Monksdream Monksdream 1 year ago
https://ih.advfn.com/markets/nasdaq/premarket
👍️0

Your Recent History

Delayed Upgrade Clock